| Citation: |
ZHU Honghong, MA Zhongshuang, LIU Ying. Change in levels of molecules related to inflammation and immune regulation in peripheral blood of patients with lupus nephritis and their values in predicting prognosis[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 110-115, 120. DOI: 10.7619/jcmp.20243153
|
To analyze the change in levels of high mobility group box 1 protein (HMGB1), interleukin-32 (IL-32), matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) in peripheral blood of patients with lupus nephritis (LN) and their values in predicting prognosis.
A total of 86 patients with LN from October 2021 to June 2023 were selected and treated with induction therapy for 6 months. Based on remission status of the disease, patients were divided into remission group (n=66) and non-responder group (n=20). Baseline data, change in levels and reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1, and the partial correlation of reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels in peripheral blood with treatment response as well as their predictive values for treatment response were compared between the two groups. Disease progression was compared between patients with different reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1.
HMGB1, IL-32 and MMP-9/TIMP-1 levels in the remission group decreased significantly at 1 and 3 months after treatment compared to before treatment (P < 0.05); the levels of HMGB1, IL-32 and MMP-9/TIMP-1 in the remission group were significantly lower than those in the non-responder group at 1 and 3 months after treatment (P < 0.05); the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels in the remission group were significantly higher than those in the non-responder group at 1 and 3 months after treatment (P < 0.05). Partial correlation analysis showed that the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels were independently significantly correlated with treatment response (P < 0.05). One and three months after treatment, the values of the area under the curve (AUC) for the combined prediction of remission by the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels were 0.910 and 0.932 respectively, with the AUC being the largest at 3 months after treatment (P < 0.05). Patients were divided into high and low reduction rate subgroups based on theoptimal cut-off value from the ROC curve analysis at 3 months after treatment, and the disease progression rate was significantly lower in the high reduction rate subgroup than in the low reduction rate subgroup for HMGB1, IL-32 and MMP-9/TIMP-1 (P < 0.05).
The great change in levels of HMGB1, IL-32 and MMP-9/TIMP-1 in peripheral blood of LN patients is significantly correlated with treatment response and disease progression, and the combined detections of HMGB1, IL-32 and MMP-9/TIMP-1 levels at 1 and 3 months after treatment have high value in predicting the treatment response of LN patients.
| [1] |
鲍星兰, 王丹丹, 靳子义, 等. 脐带间充质干细胞移植治疗难治性狼疮性肾炎的远期预后分析[J]. 实用临床医药杂志, 2023, 27(10): 1-5, 20. doi: 10.7619/jcmp.20230609
|
| [2] |
陈刚, 王小芳. 脂代谢紊乱与系统性红斑狼疮相关性研究[J]. 中华实用诊断与治疗杂志, 2017, 31(6): 554-555.
|
| [3] |
MOK C C, ONNO TENG Y K O, SAXENA R, et al. Treatment of lupus nephritis: consensus, evidence and perspectives[J]. Nat Rev Rheumatol, 2023, 19(4): 227-238. doi: 10.1038/s41584-023-00925-5
|
| [4] |
HISHAM F A, THARWAT S, SAMRA N E, et al. High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: a possible relation to lupus nephritis[J]. Lupus, 2022, 31(14): 1777-1785. doi: 10.1177/09612033221132484
|
| [5] |
丁昕宇, 李平, 白羽, 等. 狼疮性肾炎患者血清白细胞介素-32及肾损伤分子-1水平变化[J]. 中华实用诊断与治疗杂志, 2020, 34(1): 48-51.
|
| [6] |
唐莉, 王鹏军, 曹李娜, 等. 狼疮性肾炎患者血清中基质金属蛋白酶-9、基质金属蛋白酶抑制因子-1的表达水平及其意义[J]. 广西医学, 2018, 40(22): 2688-2691.
|
| [7] |
中国狼疮肾炎诊断和治疗指南编写组. 中国狼疮肾炎诊断和治疗指南[J]. 中华医学杂志, 2019, 99(44): 3441-3455. doi: 10.3760/cma.j.issn.0376-2491.2019.44.001
|
| [8] |
高丹, 路漫漫. 狼疮性肾炎患者临床病理特征及远期预后影响因素分析[J]. 中华实用诊断与治疗杂志, 2022, 36(1): 59-63.
|
| [9] |
张国珍, 徐志泉, 周朝艾, 等. 儿童狼疮性肾炎46例临床特点及治疗随访观察[J]. 中国医学前沿杂志: 电子版, 2018, 10(8): 26-29.
|
| [10] |
边彩月, 秦艺璐, 梁舒, 等. 血清和尿液联合检测免疫球蛋白结合蛋白1在狼疮性肾炎中的预测价值[J]. 实用临床医药杂志, 2024, 28(10): 83-86, 95. doi: 10.7619/jcmp.20233945
|
| [11] |
LAKSHMI V R, VANGALA N, UPPIN M S, et al. Revisiting vasculopathy in lupus nephritis: a renal biopsy evaluation study[J]. Indian J Nephrol, 2022, 32(1): 28-33. doi: 10.4103/ijn.IJN_131_20
|
| [12] |
LI S J, RUAN D D, WU W Z, et al. Potential regulatory role of the Nrf2/HMGB1/TLR4/NF-κB signaling pathway in lupus nephritis[J]. Pediatr Rheumatol Online J, 2023, 21(1): 130.
|
| [13] |
SHEN J, ZHANG M Y, PENG M Y. Progress of exosome research in systemic lupus erythematosus[J]. Cytokine X, 2022, 4(2/3): 100066.
|
| [14] |
ZICKERT A, PALMBLAD K, SUNDELIN B, et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis[J]. Arthritis Res Ther, 2012, 14(1): R36. http://www.researchgate.net/profile/Kevin_Tracey/publication/221845972_Renal_expression_and_serum_levels_of_high_mobility_group_box_1_protein_in_lupus_nephritis/links/0fcfd50868f9410944000000
|
| [15] |
张玮, 杨冉, 郭惠芳, 等. HMGB1和TNFAIP3在狼疮性肾炎系膜细胞增殖中的作用[J]. 中国药理学通报, 2017, 33(8): 1109-1113.
|
| [16] |
FENG X J, YANG R, TIAN Y X, et al. HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis[J]. J Cell Physiol, 2020, 235(6): 5111-5119. http://pubmed.ncbi.nlm.nih.gov/31667864/
|
| [17] |
ADAWY A, LI L B, HIRAO H, et al. Potential involvement of IL-32 in cell-to-cell communication between macrophages and hepatoblastoma[J]. Pediatr Surg Int, 2023, 39(1): 275.
|
| [18] |
李莉, 张老追, 李玲玲, 等. 狼疮性肾炎患者血清和尿液中IL-32和KIM-1的表达水平及临床意义[J]. 河北医药, 2019, 41(3): 361-364, 369.
|
| [19] |
BONADIO A, OGUCHE S, LAVY T, et al. Computational design of matrix metalloprotenaise-9 (MMP-9) resistant to auto-cleavage[J]. Biochem J, 2023, 480(14): 1097-1107. http://www.semanticscholar.org/paper/5a3cadaecc2338b5a1ac95f201cb406b26b8a599
|
| [20] |
ENE C D, NICOLAE I. The inflammatory profile orchestrated by inducible nitric oxide synthase in systemic lupus erythematosus[J]. J Pers Med, 2023, 13(6): 934.
|
| [21] |
HASSAN N H, YOUSEF D M, ALSEMEH A E. Hesperidin protects against aluminum-induced renal injury in rats via modulating MMP-9 and apoptosis: biochemical, histological, and ultrastructural study[J]. Environ Sci Pollut Res Int, 2023, 30(13): 36208-36227. doi: 10.1007/s11356-022-24800-0
|
| [22] |
NTRINIAS T, PAPASOTIRIOU M, BALTA L, et al. Biomarkers in progressive chronic kidney disease. still a long way to go[J]. Pril, 2019, 40(3): 27-39. http://pubmed.ncbi.nlm.nih.gov/32109222/
|
| [23] |
YAMAKOSHI S, NAKAMURA T, MORI N, et al. Effects of exercise training on renal interstitial fibrosis and renin-angiotensin system in rats with chronic renal failure[J]. J Hypertens, 2021, 39(1): 143-152. http://pubmed.ncbi.nlm.nih.gov/32833922/
|
| [24] |
BAUVOIS B, MOTHU N, NGUYEN J, et al. Specific changes in plasma concentrations of matrix metalloproteinase-2 and-9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis[J]. Nephrol Dial Transplant, 2007, 22(4): 1115-1122. http://europepmc.org/abstract/MED/17205957
|
| [25] |
DO VALLE G T, RICCI S T, SILVA A O, et al. Ethanol consumption increases renal dysfunction and mortality in a mice model of sub-lethal sepsis[J]. Can J Physiol Pharmacol, 2021, 99(7): 699-707. http://www.xueshufan.com/publication/3113136266
|
| 1. |
殷华芳，沙莎，蔡依玲，于波，刘佳，何佳，孙玲娣，王坚. 宫颈癌放射治疗相关卵巢损伤的分子机制及防治策略研究进展. 实用临床医药杂志. 2024(10): 141-144 .
 本站查看
| |
| 2. |
张玉洲，李晓敏，孙少霖. 蓝萼乙素通过Akt/BAD通路对宫颈癌裸鼠移植瘤生长的影响. 现代药物与临床. 2024(06): 1384-1389 .
| |
| 3. |
沈静，张丽华，徐晶晶，吕萌萌，吴东辰. 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响. 现代生物医学进展. 2024(13): 2592-2595 .
| |
| 4. |
曾美男. 早期宫颈癌术后不同治疗方法的临床效果分析. 实用妇科内分泌电子杂志. 2023(24): 28-30+85 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: